Translating the Rapidly Evolving CAR-TCR Research Portfolio to Clinical Practice, a Single Institution Experience at an Academic Medical Center
This is an unparalleled time in cancer research, particularly with the use of cellular therapeutics to target both solid and liquid tumors. This science is challenging the boundaries of clinical care to update guidelines, streamline processes, and integrate clinical and research teams.The University of Kansas Cancer Center was launched into the cell therapy space when we enrolled the first adult patient on Novartis Juliet CAR-T trial for DLBCL. Our team learned that inpatient and outpatient infrastructure and multidisciplinary collaboration are essential to promoting quality clinical care to complement this innovative new field of cellular immunotherapy.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Dana Wheeler, Erin Winters Tags: 409 Source Type: research
More News: Academia | Biology | Cancer | Cancer & Oncology | Hematology | Immunotherapy | Science | Transplants